Time: 15:00 - 18:00
The discovery and development of T-cell redirecting modalities, such as bispecific antibodies and CAR-Ts, holds great promise for patients with multiple myeloma and other hematological malignancies, such as lymphoma and acute myeloid leukemia.
Johnson & Johnson Innovation, in collaboration with Janssen Research & Development, LLC’s Oncology Therapeutic Area, will host a virtual scientific and strategic partnering event on state-of-the-art developments in immune cell engagers in hematological malignancies, bringing together entrepreneurs, start-ups, researchers, and scientists from across Europe and beyond. They also want to explore how Johnson & Johnson Innovation could collaborate with the aim to support opportunities and enable innovators and their innovations to reach full therapeutic potential for patients.
DANSK BIOTEK members are most welcome to join on September 7. Registration and information on speakers can be found here.